The Leducq Foundation is seeking better treatment options for patients with advanced rheumatic heart disease who live in low and middle income settings. Current options for these patients are quite limited. One promising technology is the polymeric prosthetic heart valves which hold the potential to be durable and non-thrombogenic. The Foundation is currently conducting a review of the polymeric heart valve landscape in order to understand how best to support research in this field.
We have assembled a Heart Valve Advisory Committee composed of:
- Todd Rosengart, MD, Baylor College of Medicine
- Stan Rowe, CEO, Nidus Biomedical
- Craig Sable, MD, Children’s National
- Joseph Woo, MD, Stanford University